Ticker brief
BHVN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
30
authors 14d
18
crowd 14d
+1.8σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-25 → 2026-08-28 · now +0.40 (−1 bearish … +1 bullish)
Who spoke18
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 6 | +0.34 |
| @Quantumup1 | C | · | 5 | +0.28 |
| @PersimmonTI | A | -0.57 | 2 | +0.60 |
| @Brad_E_Schulz | C | · | 2 | +0.40 |
| @BiopharmIQ | B | · | 2 | +0.33 |
| @GnT_Trades | C | +1.70 | 1 | +0.40 |
| @BioStocks | C | -3.02 | 1 | +0.50 |
| @doublejtrading | C | -1.82 | 1 | +0.00 |
| @fwpharma | B | +0.98 | 1 | +0.50 |
| @OzmosiHealth | C | · | 1 | +0.30 |
| @OptionRunners | C | +1.20 | 1 | +0.35 |
| @akishore | C | -1.38 | 1 | +0.40 |
| @BPharmCatalyst | C | · | 1 | +0.50 |
| @SteveDJacobs | C | -1.22 | 1 | +0.20 |
| @OptionsFlowBoss | C | · | 1 | +0.00 |
| @kkernttb | C | -2.19 | 1 | +0.00 |
| @ClassicRoy | C | -1.52 | 1 | +0.00 |
| @cfaryanoconnell | C | -1.48 | 1 | +0.00 |
Recent signals30of 30 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @BiopharmIQ | +0.40 | Summarizes major weekly biotech gainers and BTAI's bankruptcy-driven 75% decline | · | tweet ↗ |
| 2026-08-28 | @Quantumup1 | +0.40 | TD Cowen reiterates Buy and a $30 target, citing attractive deal economics and runway. | · | tweet ↗ |
| 2026-08-27 | @cfaryanoconnell | +0.00 | The author lists the first six stocks with increasing unusual options volume, without direction. | · | tweet ↗ |
| 2026-08-27 | @ClassicRoy | +0.00 | Lists stocks with increasing unusual options volume without directional breakdown. | · | tweet ↗ |
| 2026-08-27 | @semodough | +0.25 | Lists BHVN clinical, regulatory and deal catalysts with expected dates and cash payments. | · | tweet ↗ |
| 2026-08-27 | @kkernttb | +0.00 | Posts an updated multi-name chart watchlist without stated trade entries. | · | tweet ↗ |
| 2026-08-27 | @OptionsFlowBoss | +0.00 | Flags open-interest changes, with direction visible only in attached media. | · | tweet ↗ |
| 2026-08-26 | @PersimmonTI | +0.75 | Started a BHVN position and wishes the initial size had been larger. — Discloses a new BHVN entry and gives a detailed bullish derisking thesis. | · | tweet ↗ |
| 2026-08-26 | @Brad_E_Schulz | +0.60 | Lists stocks gaining at least 4% on at least 1.5 times average volume. | · | tweet ↗ |
| 2026-08-26 | @SteveDJacobs | +0.20 | Publishes a Thursday stock watchlist based on named technical and momentum-screen badges. | · | tweet ↗ |
| 2026-08-26 | @BPharmCatalyst | +0.50 | BHVN secures a Kv7 licensing deal worth $400M immediately and up to $795M plus royalties. | · | tweet ↗ |
| 2026-08-26 | @Quantumup1 | +0.35 | Expects the Kv7 sale to reduce Biohaven headcount by about 35%. | · | tweet ↗ |
| 2026-08-26 | @akishore | +0.40 | Reports Biohaven's global licensing deal worth up to $795M and the resulting 22% surge. | · | tweet ↗ |
| 2026-08-26 | @semodough | +0.25 | Notes 18 million shares short and suggests shorts may be wrong after financing. | · | tweet ↗ |
| 2026-08-26 | @OptionRunners | +0.35 | Reports BHVN's 26% daily move and uncertainty over continued share ownership. | · | tweet ↗ |
| 2026-08-26 | @BiopharmIQ | +0.25 | Lists biotech opening moves and associated catalysts across multiple names. | · | tweet ↗ |
| 2026-08-26 | @semodough | +0.35 | Cantor sees strategic-partnership efforts as a positive signal for funding Biohaven operations. | · | tweet ↗ |
| 2026-08-26 | @semodough | +0.50 | Baird calls transferring clinical risk and expenses for cash a net win that extends runway. | · | tweet ↗ |
| 2026-08-26 | @Brad_E_Schulz | +0.20 | Watch-list identifies high-volume stocks up at least 4%. | · | tweet ↗ |
| 2026-08-26 | @Quantumup1 | -0.10 | Raymond James retains Strong Buy but cuts Biohaven's target to $30 from $50. | · | tweet ↗ |
| 2026-08-26 | @OzmosiHealth | +0.30 | Biohaven entered a global licensing agreement with SK Biopharmaceuticals. | · | tweet ↗ |
| 2026-08-26 | @fwpharma | +0.50 | SK Bio agrees to pay $795M for Biohaven's Kv7 platform and epilepsy asset. | · | tweet ↗ |
| 2026-08-26 | @Quantumup1 | +0.40 | Argues the Kv7 sale could reduce Biohaven cash burn by one-half to three-quarters. | · | tweet ↗ |
| 2026-08-26 | @semodough | +0.20 | Says the BHVN deal underscores OVID's undervalued platform into year-end and 2027. | · | tweet ↗ |
| 2026-08-26 | @Quantumup1 | +0.35 | Argues the sold Kv7 program was the main driver of Biohaven's cash burn. | · | tweet ↗ |
| 2026-08-26 | @doublejtrading | +0.00 | Gapper watchlist names stocks without expressing direction | · | tweet ↗ |
| 2026-08-26 | @semodough | +0.50 | Details SK Biopharmaceuticals' Kv7 platform deal with up to $795M in payments and royalties. | · | tweet ↗ |
| 2026-08-26 | @PersimmonTI | +0.45 | Biohaven signs a global licensing deal with $400M near-term cash plus milestones and royalties. | · | tweet ↗ |
| 2026-08-26 | @BioStocks | +0.50 | Biohaven licensed its Kv7 platform and Opakalim to SK Biopharm for $350M upfront. | · | tweet ↗ |
| 2026-08-25 | @GnT_Trades | +0.40 | Reports BHVN reclaiming its 50-day average after nearly two months of basing. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.